These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 14696119)

  • 1. Recombinant single-chain antibody fusion construct targeting human melanoma cells and containing tumor necrosis factor.
    Liu Y; Cheung LH; Marks JW; Rosenblum MG
    Int J Cancer; 2004 Feb; 108(4):549-57. PubMed ID: 14696119
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improved expression of a soluble single chain antibody fusion protein containing tumor necrosis factor in Escherichia coli.
    Kim S; Cheung LH; Zhang W; Rosenblum MG
    Appl Microbiol Biotechnol; 2007 Nov; 77(1):99-106. PubMed ID: 17703297
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The antimelanoma immunocytokine scFvMEL/TNF shows reduced toxicity and potent antitumor activity against human tumor xenografts.
    Liu Y; Zhang W; Cheung LH; Niu T; Wu Q; Li C; Van Pelt CS; Rosenblum MG
    Neoplasia; 2006 May; 8(5):384-93. PubMed ID: 16790087
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytotoxic and antitumor activity of a recombinant tumor necrosis factor-B1(Fv) fusion protein on LeY antigen-expressing human cancer cells.
    Scherf U; Benhar I; Webber KO; Pastan I; Brinkmann U
    Clin Cancer Res; 1996 Sep; 2(9):1523-31. PubMed ID: 9816329
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization and mechanistic studies of a novel melanoma-targeting construct containing IκBa for specific inhibition of nuclear factor-κB activity.
    Zhou H; Liu Y; Cheung LH; Kim S; Zhang W; Mohamedali KA; Anand P; Hittelman WN; Aggarwal BB; Rosenblum MG
    Neoplasia; 2010 Oct; 12(10):766-77. PubMed ID: 20927315
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vivo tumor delivery of a recombinant single chain Fv::tumor necrosis factor-alpha fusion [correction of factor: a fusion] protein.
    Cooke SP; Pedley RB; Boden R; Begent RH; Chester KA
    Bioconjug Chem; 2002; 13(1):7-15. PubMed ID: 11792173
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multi-modality therapeutics with potent anti-tumor effects: photochemical internalization enhances delivery of the fusion toxin scFvMEL/rGel.
    Selbo PK; Rosenblum MG; Cheung LH; Zhang W; Berg K
    PLoS One; 2009 Aug; 4(8):e6691. PubMed ID: 19690617
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel recombinant fusion toxin targeting HER-2/NEU-over-expressing cells and containing human tumor necrosis factor.
    Rosenblum MG; Horn SA; Cheung LH
    Int J Cancer; 2000 Oct; 88(2):267-73. PubMed ID: 11004679
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted apoptosis activation with GrB/scFvMEL modulates melanoma growth, metastatic spread, chemosensitivity, and radiosensitivity.
    Liu Y; Zhang W; Niu T; Cheung LH; Munshi A; Meyn RE; Rosenblum MG
    Neoplasia; 2006 Feb; 8(2):125-35. PubMed ID: 16611405
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted delivery of human pro-apoptotic enzymes to tumor cells: In vitro studies describing a novel class of recombinant highly cytotoxic agents.
    Liu Y; Cheung LH; Hittelman WN; Rosenblum MG
    Mol Cancer Ther; 2003 Dec; 2(12):1341-50. PubMed ID: 14707275
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A quantitative analysis of tumor specific monoclonal antibody uptake by human melanoma xenografts: effects of antibody immunological properties and tumor antigen expression levels.
    Shockley TR; Lin K; Sung C; Nagy JA; Tompkins RG; Dedrick RL; Dvorak HF; Yarmush ML
    Cancer Res; 1992 Jan; 52(2):357-66. PubMed ID: 1728407
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, expression, purification, and characterization, in vitro and in vivo, of an antimelanoma single-chain Fv antibody fused to the toxin gelonin.
    Rosenblum MG; Cheung LH; Liu Y; Marks JW
    Cancer Res; 2003 Jul; 63(14):3995-4002. PubMed ID: 12873997
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted Delivery of TNF Potentiates the Antibody-Dependent Cell-Mediated Cytotoxicity of an Anti-Melanoma Immunoglobulin.
    Murer P; Kiefer JD; Plüss L; Matasci M; Blümich SL; Stringhini M; Neri D
    J Invest Dermatol; 2019 Jun; 139(6):1339-1348. PubMed ID: 30543899
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted interleukin 2 therapy enhances protective immunity induced by an autologous oral DNA vaccine against murine melanoma.
    Niethammer AG; Xiang R; Ruehlmann JM; Lode HN; Dolman CS; Gillies SD; Reisfeld RA
    Cancer Res; 2001 Aug; 61(16):6178-84. PubMed ID: 11507070
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A genetically engineered single-chain FV/TNF molecule possesses the anti-tumor immunoreactivity of FV as well as the cytotoxic activity of tumor necrosis factor.
    Yang J; Moyana T; Xiang J
    Mol Immunol; 1995 Aug; 32(12):873-81. PubMed ID: 7565814
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intratumoral vaccination of adenoviruses expressing fusion protein RM4/tumor necrosis factor (TNF)-alpha induces significant tumor regression.
    Wright P; Zheng C; Moyana T; Xiang J
    Cancer Gene Ther; 1998; 5(6):371-9. PubMed ID: 9917092
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TNF-Selectokine: a novel prodrug generated for tumor targeting and site-specific activation of tumor necrosis factor.
    Wüest T; Gerlach E; Banerjee D; Gerspach J; Moosmayer D; Pfizenmaier K
    Oncogene; 2002 Jun; 21(27):4257-65. PubMed ID: 12082613
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Targeting studies of humanized scFv25 fusing to TNFalpha against hepatocellular carcinoma].
    Sun Z; Liu Y; Yuan Q; Yu W; Huang C; Ma L; Yu J
    Zhonghua Gan Zang Bing Za Zhi; 2000 Dec; 8(6):352-4. PubMed ID: 11135695
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A tetravalent single-chain antibody-streptavidin fusion protein for pretargeted lymphoma therapy.
    Schultz J; Lin Y; Sanderson J; Zuo Y; Stone D; Mallett R; Wilbert S; Axworthy D
    Cancer Res; 2000 Dec; 60(23):6663-9. PubMed ID: 11118050
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting and therapy of carcinoembryonic antigen-expressing tumors in transgenic mice with an antibody-interleukin 2 fusion protein.
    Xu X; Clarke P; Szalai G; Shively JE; Williams LE; Shyr Y; Shi E; Primus FJ
    Cancer Res; 2000 Aug; 60(16):4475-84. PubMed ID: 10969795
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.